Beranda › Kanker Ovarium › Minnesota › Rochester
Uji klinis Kanker Ovarium di Rochester, MN
29 studi untuk Kanker Ovarium mencari peserta di lokasi sekitar Rochester (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
Menerima pesertaFase 2/3
- Mayo Clinic in Rochester, Rochester
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Menerima pesertaFase 2
- Mayo Clinic in Rochester, Rochester
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
Menerima pesertaStudi observasional
- Mayo Clinic, Rochester
Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study
Menerima peserta
- Mayo Clinic, Rochester
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Menerima pesertaStudi observasional
- Mayo Clinic Rochester, Rochester
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Menerima pesertaFase 1/2
- Mayo Clinic - Rochester, Rochester
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Menerima pesertaFase 3
- Mayo Clinic in Rochester, Minnesota, Rochester
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Menerima pesertaFase 1
- Mayo Clinic - Rochester, Rochester
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Menerima pesertaFase 1/2
- Mayo Rochester, Rochester
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Menerima pesertaStudi observasional
- Mayo Clinic (Rochester), Rochester
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Menerima peserta
- Mayo Clinic in Rochester, Rochester
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Menerima pesertaFase 3
- Mayo Clinic in Rochester, Rochester
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Menerima pesertaFase 1/2
- Mayo Clinic (Minnesota), Rochester
Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
Menerima pesertaFase 3
- Mayo Clinic Methodist Campus, Rochester
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Menerima pesertaFase 2
- Mayo Clinic, Rochester
CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer
Menerima pesertaFase 1/2
- The Mayo Clinic, Rochester
A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
Menerima pesertaFase 1
- Mayo Clinic, Rochester
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Menerima pesertaFase 1/2
- Mayo Clinic in Rochester, Minnesota, Rochester
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Menerima pesertaFase 1/2
- Mayo Clinic - Rochester, Rochester
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Menerima pesertaFase 1/2
- Mayo Clinic Rochester, Rochester
The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia.
Menerima peserta
- Mayo Clinic, Rochester
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Menerima pesertaFase 3
- Mayo Clinic, Rochester
TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention
Menerima peserta
- Mayo Clinic, Rochester
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Menerima pesertaFase 1/2
- Mayo Clinic, Rochester
First in Human Study of TORL-1-23 in Participants With Advanced Cancer
Menerima pesertaFase 1
- Mayo Clinic in Rochester, Rochester
Ultrasound Microvessel Imaging for the Evaluation of Ovarian and Adnexal Lesions
Menerima peserta
- Mayo Clinic in Rochester, Rochester
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Menerima pesertaStudi observasionalSukarelawan sehat diterima
- Mayo Clinic, Rochester
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
Menerima pesertaFase 2
- Mayo Clinic, Rochester
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
Menerima pesertaFase 1
- Exelixis Clinical Site #14, Rochester
Uji klinis Kanker Ovarium di kota lain
- Houston, TX89 studi
- New York City, NY69 studi
- Boston, MA61 studi
- Los Angeles, CA50 studi
- Nashville, TN49 studi
- Arlington, VA46 studi
- Philadelphia, PA44 studi
- Columbus, OH39 studi
- St. Louis, MO38 studi
- Chicago, IL36 studi
- San Antonio, TX31 studi
- Cleveland, OH30 studi
Studi lain di Rochester
- Kanker Payudara42 studi
- Kanker Paru Non-Sel Kecil37 studi
- Kanker Metastatik31 studi
- Kanker (semua jenis)30 studi
- Kanker Kolorektal29 studi
- Mieloma Multipel24 studi
- Gagal Jantung22 studi
- Kanker Prostat22 studi
- Kanker Pankreas22 studi
- Kanker Endometrium20 studi
- Kanker Paru20 studi
- Leukemia Limfositik Kronis18 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.